NEO

NeoGenomics, Inc. (NEO)

Saturday, October 17, 2026
Past 1Y
MA21MA180
Signals
BuyEarly buySellEarly sellTurning points
Swing highSwing low
Up dayDown day

NeoGenomics (NEO) at a glance

Close · Aug 4, 2026
$16.29
Day change
+2.84%
52-week range
$7.07 – $16.35
Market cap
$1.5B
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NASDAQ

NeoGenomics stock: what the data says

NeoGenomics (NEO) closed at $16.29 on Aug 4, 2026, up 2.8% on the day. The stock is up 7.5% over the past month, up 81.0% over three months, up 38.5% year to date and up 215.7% over the past year. It is trading at its 52-week high of $16.35. The close sits above its 50-day moving average ($12.89) and above its 200-day moving average ($10.90).

NEO is scheduled to report earnings on Oct 26, 2026, before market open.

NEO options were pricing 67% at-the-money implied volatility on Oct 12, 2026, an IV rank of 41 over the past year.

NEO earnings

Next report
Oct 26, 2026, before market open

NEO earnings analysis →

NEO stock: key questions

When is NEO's next earnings date?

NeoGenomics is scheduled to report on Oct 26, 2026, before market open.

Is NEO above its 200-day moving average?

Yes — the Aug 4, 2026 close of $16.29 is 49.4% above the 200-day average of $10.90.

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

neogenomics.com